# Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

> **NCT00001386** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (—)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- HIV Infection

## Interventions

- **DRUG:** PCLUS 3-18 MN
- **DRUG:** PCLUS 6.1 MN

## Key facts

- **NCT ID:** NCT00001386
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-06
- **Primary completion:** —
- **Final completion:** 2002-01
- **Target enrollment:** 31 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001386, "Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00001386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*